The Burrill Report (November 8, 2010): A U.S. Policy Reversal on Gene Patents (.MP3,12.87 Mb)
The evolving legal battle over the patentability of genes heated up recently when the U.S. Department of Justice stepped into the Myriad Genetics case with an amicus brief that argues, as products of nature, genes should not be patentable. The brief breaks with long-standing federal policy on gene patents and adds to the concerns of the biotechnology industry that sees such protections as critical to the ability of the industry to attract investors. We spoke to Ken Chahine, visiting professor of law at the University of Utah, about the DOJ’s brief, the argument the government is making, and what effects this could have on the outcome of the case and the future of the industry.
November 04, 2010
http://www.burrillreport.com/article-a_u_s_policy_reversal_on_gene_patents_.html